Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

Drummond, Michael; Barbieri, Marco; Cook, J.R.; Glick, Henry A.; Lis, Joanna; Malik, Farzana; Reed, Shelby D.; Rutten, Frans; Sculpher, Mark; Severens, Johan L.

doi:10.1111/j.1524-4733.2008.00489.x

Cited by 419 publications

(381 citation statements)

References 30 publications

Supporting

Mentioning

351

Contrasting

Unclassified

Order By: Relevance

“…2 While cross-regional extrapolation of epidemiological outcomes is commonly accepted in health economic evaluations, clinical outcomes such as LOS and hospitalization rates may be less generalizable because of jurisdictional variations in socioeconomic status, practice variability, and supply of health care resources. [13][14][15] Our objective was to conduct an economic evaluation of both salbutamol inhalation methods based on local, hospitalspecific patient-level outcome and cost data.…”

Section: Introductionmentioning

confidence: 99%

A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia

Spin¹,

Sketris²,

Hill-Taylor³

et al. 2016

CJEM

View full text Add to dashboard Cite

Background: Despite evidence demonstrating the advantages of metered-dose inhalers with spacers (MDI-s), nebulization (NEB) remains the primary method of asthma treatment in some pediatric emergency departments (PEDs). There is a perception that delivering salbutamol by MDI-s is more costly than by NEB. This research evaluates the relative costs of MDI-s and NEB using local, hospital-specific, patientlevel data. Methods: Regression models estimated associations between the salbutamol inhalation method and costs, length of stay (LOS) in the PED and hospital, and the probability of admission. Our population was a random sample of 822 patients presenting with wheeze to the PED in 2008/2009. Control variables included age, sex, triage acuity, time of PED visit, other medications, and vitals. Costs were calculated using the prices and quantities of medical resources used per treatment. Probabilistic sensitivity analysis was used. Results: Treatment with MDI-s versus NEB was associated with an absolute decrease in hospitalization of 4.4% (p < 0.05) and a 25-hour (p < 0.001) reduction in average inpatient stay, after controlling for triage acuity and patient characteristics. This resulted in savings of $24/patient in the PED and $180/ patient overall (p < 0.001). Inpatient care accounted for more than 90% of total patient costs. Conclusions: Our results suggest economic gains associated with MDI-s for salbutamol inhalation in PEDs. Sensitivity analyses show that this conclusion is not affected by changes in model parameters that may differ by jurisdiction. Since most facilities already collect the data used for this study, our methods could be adopted for a cross-jurisdictional account of the cost effectiveness of MDI-s.

show abstract

Section: Introductionmentioning

confidence: 99%

A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia

Spin¹,

Sketris²,

Hill-Taylor³

et al. 2016

CJEM

View full text Add to dashboard Cite

show abstract

“…When designing studies to be transferable across jurisdictions, it is necessary to harmonize both the study/model design and data collection 60. The design of EQUIPTMOD facilitates such decisions not only in the countries participating in the first wave, as highlighted in this paper, but will allow countries with fewer analytical resources to adapt the model to provide pertinent information for their context.…”

Section: Discussionmentioning

confidence: 99%

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

Coyle

Lester‐George

et al. 2017

Addiction

View full text Add to dashboard Cite

Background and AimsAlthough clear benefits are associated with reducing smoking, there is increasing pressure on public health providers to justify investment in tobacco control measures. Decision‐makers need tools to assess the Return on Investment (ROI)/cost‐effectiveness of programmes. The EQUIPT project adapted an ROI tool for England to four European countries (Germany, the Netherlands, Spain and Hungary). EQUIPTMOD, the economic model at the core of the ROI tool, is designed to assess the efficiency of packages of smoking cessation interventions. The objective of this paper is to describe the methods for EQUIPTMOD and identify key outcomes associated with continued and cessation of smoking.MethodsEQUIPTMOD uses a Markov model to estimate life‐time costs, quality‐adjusted life years (QALYs) and life years associated with a current and former smoker. It uses population data on smoking prevalence, disease prevalence, mortality and the impact of smoking combined with associated costs and utility effects of disease. To illustrate the tool's potential, costs, QALYs and life expectancy were estimated for the average current smoker for five countries based on the assumptions that they continue and that they cease smoking over the next 12 months. Costs and effects were discounted at country‐specific rates.ResultsFor illustration, over a life‐time horizon, not quitting smoking within the next 12 months in England will reduce life expectancy by 0.66, reduce QALYs by 1.09 and result in £4961 higher disease‐related health care costs than if the smoker ceased smoking in the next 12 months. For all age–sex categories, costs were lower and QALYs higher for those who quit smoking in the 12 months than those who continued.ConclusionsEQUIPTMOD facilitates assessment of the cost effectiveness of smoking cessation strategies. The demonstrated results indicate large potential benefits from smoking cessation at both an individual and population level.

show abstract

“…This process enables different jurisdictions to assess the extent to which the findings of (model-based) economic evaluations from another jurisdiction can be adapted. For example, while parameters such as baseline patient characteristics and risk factors are jurisdiction specific, data on treatment effect (from clinical trials) and utility values might be more generalizable across jurisdictions [23]. Using disease-specific models, applicants can update jurisdiction-specific data.…”

Section: Characteristicsmentioning

confidence: 99%

Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions

et al. 2015

View full text Add to dashboard Cite

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

Cited by 419 publications

References 30 publications

A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia

A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia

Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation

Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions

Contact Info

Product

Resources

About